514 results on '"Wagner, John E."'
Search Results
2. Risk
3. Market Equilibrium and Structure
4. Revenue
5. Supply and Demand
6. Estimating Nonmarket Values
7. Production Systems
8. Capital Theory
9. Developing Business Plans
10. Introduction
11. The Natural Resources Management Puzzle
12. Profit
13. Taxes
14. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice
15. FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia
16. Development of specific growth charts for children with Fanconi anemia
17. Successful Hematopoietic Cell Transplantation in Patients with Fanconi Anemia with Severe Renal Insufficiency
18. Choosing a sample size allocation to strata based on trade-offs in precision when estimating accuracy and area of a rare class from a stratified sample
19. Forestry Economics
20. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
21. Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease
22. Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials
23. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Reduced Intensity Conditioning with Cyclophosphamide/Fludarabine/Total Body Irradiation (TBI) with Tacrolimus, MMF, and Conditional Anti Thymocyte Globulin (ATG) for the Treatment of Hematological Malignancies
24. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increase Relapse Risk Compared to Historical Cyclosporine/ Methotrexate
25. Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo
26. A Least-Cost Dynamic Optimization Approach for Obtaining a Desired Balanced Uneven-Aged Structure
27. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer
28. Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants
29. Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials
30. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
31. Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses
32. Correction of Fanconi Anemia Mutations Using Digital Genome Engineering
33. Abstract 6196: Fanconi anemia pathway deficiency drives copy number variation in squamous cell carcinoma
34. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice
35. Early Engraftment and Lymphocyte Reconstitution Outcomes after Alpha/Beta T Cell Receptor Depletion in Patients Transplanted for Fanconi Anemia
36. Hematopoietic Cell Transplantation for Fanconi Anemia
37. Regulatory T cells: A review of manufacturing and clinical utility
38. Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials
39. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
40. The Role of Spirituality
41. Fanconi Anemia Pathway Deficiency Drives Copy Number Variation in Squamous Cell Carcinomas
42. Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion
43. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
44. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
45. Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation
46. Nonhematologic neoplasia in biallelic BRCA2 mutated Fanconi anemia.
47. First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings
48. MGTA-456, A CD34 Expanded Cord Blood Product, Permits Selection of Better HLA Matched Units and Results in Rapid Hematopoietic Recovery, Uniform Engraftment and Reduced Graft-Versus-Host Disease in Adults with High-Risk Hematologic Malignancies
49. CYP2B6 Variants in Cyclophosphamide Metabolism and the Incidence of Hemorrhagic Cystitis in Fanconi Anemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
50. Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model As a Single Agent
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.